Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke
- 1 April 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 34 (4), 1038-1040
- https://doi.org/10.1161/01.str.0000063139.06585.45
Abstract
Background and Purpose— Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently identified fibrinolysis inhibitor in plasma. The purpose of this work was to study TAFI levels in the acute ph...Keywords
This publication has 9 references indexed in Scilit:
- Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosisBlood, 2000
- An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis ModelThrombosis Research, 2000
- How well does the Oxfordshire Community Stroke Project classification predict the site and size of the infarct on brain imaging?Journal of Neurology, Neurosurgery & Psychiatry, 2000
- Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery DiseaseThrombosis and Haemostasis, 2000
- A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of CoagulationThrombosis and Haemostasis, 1998
- Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1995
- Interphysician agreement in the diagnosis of subtypes of acute ischemic strokeNeurology, 1993
- Classification and natural history of clinically identifiable subtypes of cerebral infarctionThe Lancet, 1991